Designating something "safe" in this industry means acceptable risk. AI can help us improve acceptable risks if it is used appropriately. However, industry experts must be thoughtful and responsible in their use of AI within clinical trials. 
In the third episode of our mini series on artificial intelligence, our guests explore the challenges and benefits of integrating technology into the lives of patients.
 
Host
<a href="https://www.linkedin.com/in/lorielliskatz/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace
 
Guests
<a href="https://www.linkedin.com/in/michaeljking/" rel="ugc noopener noreferrer" target="_blank">⁠⁠Mike King⁠⁠⁠</a>, Senior Director of Product and Strategy, IQVIA
<a href="https://www.linkedin.com/in/movosto/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠⁠Moritz von Stosch⁠⁠⁠⁠</a> Chief Innovation Officer, DataHow
<a href="https://www.linkedin.com/in/nindhanaparanthaman/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠Nindhana Paranthaman⁠⁠⁠</a>, Executive Medical Director, Clinical Development, Summit Therapeutics
<a href="https://www.linkedin.com/in/paul-agapow/" rel="ugc noopener noreferrer" target="_blank">⁠⁠⁠⁠Paul Agapow⁠⁠⁠⁠</a>, Head of Data Science, BioNTech

Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.